2. PI3K/Akt/mTOR MAPK/ERK Pathway
  3. mTOR Ribosomal S6 Kinase (RSK)
  4. Coronarin A

Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research.

For research use only. We do not sell to patients.

Coronarin A Chemical Structure

Coronarin A Chemical Structure

CAS No. : 119188-33-9

Size Price Stock Quantity
1 mg In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Coronarin A Related Antibodies

Top Publications Citing Use of Products

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

View All Ribosomal S6 Kinase (RSK) Isoform Specific Products:

View All Isoforms
p70S6K RSK1 RSK2 RSK3 RSK4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research[1].

IC50 & Target[1]

mTORC1

 

S6K1

 

Cellular Effect
Cell Line Type Value Description References
HUVEC IC50
4.22 μg/mL
Compound: 1
Growth inhibitory activity against human umbilical vein endothelial cells (HUVEC) proliferation using MTT colorimetric method
Growth inhibitory activity against human umbilical vein endothelial cells (HUVEC) proliferation using MTT colorimetric method
[PMID: 12781184]
In Vitro

Coronarin A (3-30?μM; 4 or 12 h) stimulates glycogen synthesis through activating PI3K/Akt/GSK3β signaling and inhibits gluconeogenesis by activating ERK-dependent Wnt/β-catenin/TCF7L2 pathway in rat primary hepatocytes[1].
Coronarin A (1-30 μM; 4 h) increases tyrosine phosphorylation of IRS1 through inhibiting mTOR/S6K1 signaling[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Coronarin A Related Antibodies

Western Blot Analysis[1]

Cell Line: Primary rat hepatocytes
Concentration: 1, 3, 10 and 30 μM
Incubation Time: 4 h
Result: Increased the Akt and GSK3β phosphorylation dose-dependently. Dose-dependently stimulated the phosphorylation of both ERK1 and ERK2. Increased the phosphorylation of β-catenin and mitogen-activated protein kinase kinase (MEK). Dose-dependently enhanced the tyrosine phosphorylation of IRS1 at Tyr1222, whereas the serine phosphorylation of IRS1 was dose-dependently inhibited. Reduced the phosphorylation of mTOR, S6K1 and S6.

Cell Viability Assay[1]

Cell Line: Primary rat hepatocytes
Concentration: 1, 3, 10, 30, 100 and 300 μM
Incubation Time: 5.5 h or 12 h
Result: Showed no toxicity at 1-30 μM, decreased cell viability after 12 h incubation at 100 μM.
In Vivo

Coronarin A (30 or 100 mg/kg; i.p. or p.o.; once daily for 22 days) ameliorates hyperglycemia in mice[1].
Coronarin A (100 mg/kg; p.o.; once daily for 22 days) inhibits the mTOR/S6K1 pathway to activate PI3K/Akt and ERK/β-catenin signaling in livers of ob/ob mice[1].
Pharmacokinetic properties of Coronarin A after single administrationa in ob/ob mice[1].

Coronarin A t1/2 (h) tmax (h) Cmax (ng/mL) AUC0-t (ng·h/mL) AUC0-∞ (ng·h/mL) MRT (h)
i.p. 14.8 1.0 1073 4571 11045 21.7
p.o. 3.01 1.0 388 1694 1856 4.88

Data are presented as the mean of three mice.
aCoronarin A was intraperitoneally or orally administered at 30 mg/kg to ob/ob mice.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ob/ob mice[1]
Dosage: 30 mg/kg (IP) or 100 mg/kg (PO)
Administration: Oral or intraperitoneal administration, once daily for 22 days
Result: Significantly decreased the non-fasting and fasting blood glucose. Significantly reduced the serum insulin concentration at 15 min after glucose loading, reduced the average daily food intake while the body weight was unaffected. Increased hepatic glycogen content and the expression levels of gluconeogenic gene Pck1 and G6pc were significantly decreased.
Animal Model: Female ob/ob mice[1]
Dosage: 30 mg/kg
Administration: Intraperitoneal or oral administration (Pharmacokinetic Analysis)
Result: Intraperitoneal injection exhibited higher plasma exposure than oral gavage at the same dose of 30 mg/kg, with Cmax value of 1073 and 388 ng/mL, respectively.
Molecular Weight

300.44

Formula

C20H28O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1([C@H]2/C=C/C3=COC=C3)[C@@](C(C)(CCC1)C)([H])C[C@H](O)C2=C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 10 mg/mL (33.28 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3285 mL 16.6423 mL 33.2845 mL
5 mM 0.6657 mL 3.3285 mL 6.6569 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: ≥98.0%

SDS (251 KB)

COA (253 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.3285 mL 16.6423 mL 33.2845 mL 83.2113 mL
5 mM 0.6657 mL 3.3285 mL 6.6569 mL 16.6423 mL
10 mM 0.3328 mL 1.6642 mL 3.3285 mL 8.3211 mL
15 mM 0.2219 mL 1.1095 mL 2.2190 mL 5.5474 mL
20 mM 0.1664 mL 0.8321 mL 1.6642 mL 4.1606 mL
25 mM 0.1331 mL 0.6657 mL 1.3314 mL 3.3285 mL
30 mM 0.1109 mL 0.5547 mL 1.1095 mL 2.7737 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Coronarin A Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Coronarin A119188-33-9mTORRibosomal S6 Kinase (RSK)Mammalian target of RapamycinS6KT2DMtype 2 diabetes mellitusgluconeogenesisglycogen synthesisMEKERK1/2β-cateninTCF7L2PI3K/Akt/GSK3βERK/Wnt/β-cateninIRS1mTORC1S6K1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Coronarin A
Cat. No.:
HY-N3628
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.